What Is a Liquid Biopsy?
Definition, origins, and core principles
A liquid biopsy (also called a fluid biopsy) is a non-invasive diagnostic technique that detects tumor-derived biological markers circulating in body fluids — primarily blood, but also urine, saliva, or cerebrospinal fluid. Unlike a conventional biopsy that requires surgically removing a piece of solid tissue, a liquid biopsy captures the cancer's genomic information from a simple blood draw.
Core Principle
Tumor cells continuously shed tiny fragments of DNA, RNA, and other molecules into the bloodstream. Liquid biopsy analyzes these fragments to identify the mutations present in the tumor — all without touching it directly.
Historical Background
The concept emerged in the 1970s with the discovery of cell-free circulating DNA. The first major clinical application was FDA-approved in 2016: the cobas® EGFR Mutation Test v2 for non-small cell lung cancer.
Clinical Applications
Early screening, diagnosis, therapy selection (targeted treatments), treatment response monitoring, drug resistance detection, and Minimal Residual Disease (MRD) surveillance after therapy completion.
A Promising Future
Multi-Cancer Early Detection (MCED) tests such as Galleri® (GRAIL) aim to simultaneously detect signals from over 50 cancer types in a single blood sample, opening the door to population-wide cancer screening.
Key Biomarkers Analyzed
The molecular targets detectable in body fluids
DNA fragments shed by cancer cells. Carries cancer-specific mutations. The most studied and clinically used biomarker in liquid biopsy today.
Total DNA present in blood plasma, including both tumor-derived DNA (ctDNA) and DNA from healthy cells. The foundation of most commercial tests.
Intact cancer cells that have detached from the primary tumor and circulate in the bloodstream. Useful for studying the full tumor phenotype and metastatic potential.
Messenger RNA and microRNA released by tumor cells. Reflects the active gene expression of the tumor, complementing DNA-based analysis.
Nano-sized membrane vesicles secreted by tumor cells, carrying DNA, RNA, and proteins. Offer a unique window into tumor biology and intercellular signaling.
Cancer-specific proteins and peptides expressed or overexpressed by malignant cells, detectable in plasma or urine. Include well-known markers like PSA, CA-125, and CEA.
Technical Note: The majority of FDA-approved clinical tests focus on analyzing ctDNA in blood plasma, as it is the best-characterized biomarker and the one for which Next-Generation Sequencing (NGS) technologies offer the highest analytical sensitivity and clinical validation.
Advantages of Liquid Biopsy
Why this technique is transforming cancer diagnosis and monitoring
Non-Invasive & Surgical Risk-Free
Only a standard blood draw is required — no anesthesia, no incision, no risk of post-biopsy complications such as infection, bleeding, or pneumothorax. Ideal for fragile or elderly patients.
Repeatable & Longitudinal Monitoring
Can be performed as many times as needed to track tumor evolution in real time, monitor treatment response, detect relapse, or identify emerging resistance mutations without additional patient burden.
Panoramic View of Tumor Heterogeneity
Simultaneously captures genomic signals from all tumor lesions — primary tumor and distant metastases — overcoming the focal sampling limitation of traditional tissue biopsy.
Faster Results
Turnaround times average 1–2 weeks compared to 4–6 weeks for some tissue biopsies, enabling earlier treatment decisions and faster patient access to precision therapies.
Precision Therapy Guidance
Identifies actionable mutations (EGFR, KRAS, BRAF, ALK, ROS1, HER2, PIK3CA, and more) to match patients with the most appropriate targeted therapies or immunotherapy agents.
Early Detection & Population Screening
Tests like Galleri® (GRAIL) aim to detect a cancer signal years before clinical symptoms appear, potentially enabling multi-cancer population-level screening programs in the near future.
Alternative When Biopsy Is Not Feasible
Essential for surgically inaccessible tumors (certain lung, brain, or pancreatic cancers) or for patients whose general condition contraindicates any invasive procedure.
Minimal Residual Disease (MRD) Detection
Detects trace amounts of residual cancer cells after treatment (surgery, chemotherapy, radiation), predicting relapse risk well before clinical recurrence — allowing earlier therapeutic intervention.
Patient Preference: In clinical surveys, more than 90% of patients prefer liquid biopsy over tissue biopsy when both options are available, citing its non-invasive nature and minimal impact on quality of life as the primary reasons.
Limitations of Liquid Biopsy
Technical and clinical challenges to consider
Variable Analytical Sensitivity
Early-stage tumors or tumors with low tumor burden shed very little ctDNA into the blood (< 0.1% of total cfDNA), significantly increasing the risk of false negatives, particularly at stages I and II.
No Histological Information
Liquid biopsy provides no data on tissue architecture, histological grade, vascular invasion, or surgical margins. A tissue biopsy is still required for the initial pathological diagnosis in most cases.
High Cost & Limited Coverage
Advanced liquid biopsy tests (full NGS panels) cost between $1,500 and $5,000. Insurance reimbursement remains partial or unavailable for many indications, creating access disparities across different patient populations.
Complex Clinical Interpretation
The clinical significance of some detected mutations — particularly those arising from CHIP (Clonal Hematopoiesis of Indeterminate Potential) — may not be cancer-related. Bioinformatics and molecular oncology specialists are required for proper interpretation.
False Positives & Benign Variants
Mutations detected may originate from normal hematopoietic cells (CHIP), inflammatory processes, or sequencing artifacts, potentially leading to unnecessary investigations and patient anxiety.
Cannot Replace Tissue Biopsy for Initial Diagnosis
For the vast majority of cancers, tissue biopsy remains the gold standard for initial diagnosis. Liquid biopsy alone cannot confirm a cancer diagnosis in most clinical scenarios and is used as a complement, not a replacement.
Insufficient Standardization
Pre-analytical variables (tube type, centrifugation timing), extraction protocols, and detection thresholds vary across laboratories, making inter-laboratory comparisons and result harmonization challenging.
Incomplete Tumor Heterogeneity Capture
Some tumors — notably low-grade gliomas and meningiomas — shed little to no ctDNA into the peripheral blood, severely limiting the utility of liquid biopsy in these specific cancer types.
Important: A negative liquid biopsy result does NOT rule out the presence of cancer. When clinical or radiological suspicion persists, a tissue biopsy remains indicated and should not be skipped on the basis of a negative liquid biopsy alone.
Liquid Biopsy vs. Tissue (Solid) Biopsy
A comprehensive head-to-head comparison of both diagnostic approaches
| Criteria | 🩸 Liquid Biopsy | 🔪 Tissue (Solid) Biopsy |
|---|---|---|
| Sample Type | Venous blood draw (5–10 mL), urine, or saliva | Surgical or percutaneous removal of a tumor tissue fragment |
| Invasiveness | ✔ Minimal — standard nursing procedure | ✘ Invasive — requires local or general anesthesia |
| Patient Risk | ✔ Negligible — bruising possible | ✘ Real risks — infection, bleeding, pneumothorax, pain |
| Repeatability | ✔ Easy — as many times as needed | ✘ Limited — each procedure carries new risks |
| Tumor Heterogeneity | ✔ Captures all lesions simultaneously | ✘ Partial — snapshot of a single tumor site only |
| Histological Information | ✘ Absent — no cell morphology data | ✔ Complete — grade, histological type, margins |
| Turnaround Time | ✔ 7–14 days on average | ~ 2–6 weeks depending on complexity |
| Sensitivity (Advanced Stages) | ✔ High (stages III–IV, abundant ctDNA) | ✔ High — diagnostic gold standard |
| Sensitivity (Early Stages) | ✘ Limited (low ctDNA concentration) | ✔ Better — direct tumor tissue analysis |
| Access to Inaccessible Tumors | ✔ Yes — location-independent | ✘ Difficult — deep-seated sites carry high procedural risk |
| On-Treatment Monitoring | ✔ Ideal — real-time disease tracking | ✘ Unsuitable — too invasive for repeated sampling |
| MRD Detection | ✔ Yes — with ultra-sensitive NGS | ✘ No — cannot detect residual traces |
| Estimated Cost (USA) | ~ $1,500 – $5,000 (full NGS panel) | ~ $500 – $3,000 depending on technique and analysis |
| Initial Diagnostic Role | ⚠ Complementary — rarely sufficient alone | ✔ Gold Standard — reference for initial diagnosis |
| Patient Comfort | ✔ Excellent — quick outpatient procedure | ✘ Variable — stress, potential recovery period |
Combined Approach: The current clinical trend is toward complementary use of both biopsy types. Tissue biopsy establishes the initial diagnosis, while liquid biopsy provides dynamic follow-up, resistance detection, and MRD monitoring — giving oncologists a comprehensive, real-time picture of disease evolution.
FDA-Approved Cancer Indications
Validated clinical indications and authorized commercial tests in the United States
The U.S. Food and Drug Administration (FDA) has approved several liquid biopsy tests under the Companion Diagnostic (CDx) or Breakthrough Device designation. These approvals guarantee the clinical use of these tests to guide therapeutic decisions for specific oncology indications, ensuring safety, accuracy, and clinical validity.
Non-Small Cell Lung Cancer (NSCLC)
First approval in 2016. Detection of EGFR mutations (exon 19 del, L858R, T790M) to guide targeted therapies (osimertinib, gefitinib, erlotinib). Also: KRAS G12C mutations, ALK, ROS1, RET, MET rearrangements.
cobas® EGFR v2 Guardant360 CDx FoundationOne Liquid CDxBreast Cancer
Detection of the PIK3CA mutation in cfDNA to guide alpelisib (Piqray®) in HR+/HER2– advanced disease. ESR1 mutations for aromatase inhibitor resistance. Circulating HER2 assessment.
therascreen® PIK3CA RGQ PCR FoundationOne Liquid CDxColorectal Cancer (CRC)
Detection of RAS mutations (KRAS / NRAS) and BRAF V600E to guide anti-EGFR therapies (cetuximab, panitumumab) and BRAF inhibitors. MSI/MMR status for immunotherapy (pembrolizumab).
Guardant360 CDx FoundationOne Liquid CDxProstate Cancer
Detection of somatic BRCA1/2 mutations in cfDNA to guide PARP inhibitors (olaparib — Lynparza®, rucaparib — Rubraca®) in metastatic castration-resistant prostate cancer (mCRPC).
FoundationOne Liquid CDx BRACAnalysis CDx®Ovarian Cancer
Detection of somatic BRCA1/2 mutations in plasma to select patients eligible for PARP inhibitors (olaparib, rucaparib, niraparib) in advanced ovarian cancer treatment and maintenance settings.
FoundationOne Liquid CDx Guardant360 CDxPan-Cancer Solid Tumors (TMB)
Detection of a high tumor mutational burden (TMB-High ≥ 10 mut/Mb) in cfDNA — tumor-agnostic indication for pembrolizumab (Keytruda®) in any advanced solid tumor refractory to prior therapies.
FoundationOne Liquid CDxLeukemias & Lymphomas
Detection of IDH1/IDH2 mutations in AML. FLT3 mutation for midostaurin eligibility. MRD assessment in CLL (chronic lymphocytic leukemia) and DLBCL (diffuse large B-cell lymphoma).
CLIA Lab Tests NGS MRD MonitoringPancreatic & Biliary Tract Cancers
Detection of KRAS G12C mutations and FGFR fusions (pemigatinib, futibatinib) in cholangiocarcinoma. NTRK fusions and BRCA mutations for pan-tumor therapies.
Guardant360 CDx FoundationOne Liquid CDxNTRK Fusion Tumors (Pan-Cancer)
Detection of NTRK1/2/3 gene fusions in cfDNA to guide TRK inhibitors (larotrectinib — Vitrakvi®, entrectinib — Rozlytrek®) in any solid tumor type, regardless of anatomical location.
FoundationOne Liquid CDx Guardant360 CDxRenal Cell Carcinoma (RCC) & GIST
Detection of FH, SDHx alterations in hereditary renal carcinomas and KIT/PDGFRA mutations in GIST to guide imatinib and second-line therapies (ripretinib, avapritinib).
FoundationOne Liquid CDxRegulatory Update (2026): The Galleri® test (GRAIL) for multi-cancer early detection (50+ cancer types) is under advanced FDA review. It has received the Breakthrough Device designation and is currently available in the USA by physician prescription. Full FDA approval is anticipated pending final data from the PATHFINDER and STRIVE clinical trials.
How a Liquid Biopsy Test Works
From physician prescription to clinical interpretation — step by step
🩺 Medical Prescription & Clinical Decision
The oncologist or specialist physician orders the test based on the suspected or confirmed cancer type, disease stage, and the specific clinical question (diagnosis, therapy selection, treatment monitoring, or MRD surveillance). The choice of test panel depends on the biomarkers to be analyzed.
🧪 Blood Sample Collection
A nurse or phlebotomist collects a standard venous blood draw of 2 to 4 specialized tubes (EDTA tubes for cfDNA, or Streck Cell-Free DNA BCT® tubes that preserve cfDNA integrity). The procedure takes 5–10 minutes. No special preparation (fasting) is required. Samples must reach the lab within 96 hours at room temperature when using Streck tubes.
🏭 Transport & Laboratory Receipt
The sample is transported under controlled conditions to a specialized, CLIA-certified laboratory. Upon receipt, a unique identifier is assigned to the sample and its conformity is verified (volume, integrity, transport temperature). A chain of custody is established for full traceability.
⚗️ cfDNA Extraction & Isolation
Plasma is separated from blood cells by double centrifugation. Cell-free DNA (cfDNA) is extracted from the plasma using specialized high-yield kits. cfDNA concentration and quality are measured by fluorometry and bioanalyzer. Typically, 1–10 ng of cfDNA is recovered per mL of plasma.
🔬 Genomic Analysis (NGS or Digital PCR)
The extracted DNA is analyzed by ultra-deep Next-Generation Sequencing (NGS) (coverage > 10,000×) or by droplet digital PCR (ddPCR) depending on the test type. Sophisticated bioinformatics algorithms distinguish true tumor mutations from sequencing errors. Panels analyze between 50 and 500+ genes depending on the assay.
🧠 Bioinformatics Interpretation & Annotation
Detected variants are filtered, classified by clinical significance (pathogenic, variant of uncertain significance, benign), and annotated with associated therapies (FDA-approved or in clinical trials). Reference databases such as ClinVar, OncoKB, and COSMIC are used for systematic interpretation and clinical relevance scoring.
📋 Clinical Report & Result Delivery
A structured report is transmitted to the ordering physician, typically 7–14 days after sample receipt. It includes: detected mutations with their variant allele frequencies (VAF), tumor mutational burden (TMB), MSI status, available targeted therapies, and relevant clinical trial options for the patient's profile.
🤝 Oncology Consultation & Treatment Decision
The oncologist discusses the results with the patient during a dedicated consultation, ideally within a multidisciplinary tumor board (MTB). The treatment decision (targeted therapy, immunotherapy, clinical trial enrollment, or watchful monitoring) is made by integrating liquid biopsy findings, imaging data, and the patient's overall clinical status.
Major Commercial Tests Available in the USA: Guardant360 CDx® (Guardant Health) — 74 genes, plasma ; FoundationOne Liquid CDx® (Foundation Medicine / Roche) — 324 genes, plasma ; Galleri® (GRAIL) — multi-cancer early detection, plasma ; OncoBEAM™ RAS CRC (Sysmex) — ddPCR, RAS mutations in CRC ; cobas® EGFR Mutation Test v2 (Roche) — EGFR in NSCLC.